SCHEMBL4529388

SCHEMBL4529388

COCc1c(C(=O)OC)sc2nc(Cc3ccc(Cl)c(Cl)c3)[nH]c(=O)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEH1 O60930 1/20 0.47
KMT2A Q03164 7/20 0.46
MAPT P10636 6/20 0.46
MEN1 O00255 5/20 0.46
MAPK1 P28482 2/20 0.46
PSMD14 O00487 1/20 0.46
KDM4E B2RXH2 4/20 0.44
PIP4K2A P48426 1/20 0.43
ALDH1A1 P00352 6/20 0.43
PDE5A O76074 1/20 0.43
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
KCNH2 Q12809 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4518657 0.93 KMT2A (0.51) RNASEH1KMT2AMAPTMEN1MAPK1
SCHEMBL3494661 0.91 RNASEH1 (0.53) RNASEH1KMT2AMAPTMEN1KDM4E
SCHEMBL21504938 0.88 KMT2A (0.58) RNASEH1KMT2AMAPTMEN1MAPK1
SCHEMBL4514505 0.79 KMT2A (0.65) RNASEH1KMT2AMAPTMEN1MAPK1
SCHEMBL3491664 0.79 RNASEH1 (0.58) RNASEH1KMT2AMAPTMEN1KDM4E
SCHEMBL38376 0.78 RNASEH1 (0.52) RNASEH1KMT2AMAPTMEN1MAPK1
SCHEMBL3492896 0.78 RNASEH1 (0.57) RNASEH1KMT2AMAPTMEN1KDM4E
SCHEMBL3492895 0.77 RNASEH1 (0.51) RNASEH1KMT2AMAPTMEN1MAPK1
SCHEMBL4507208 0.76 KMT2A (0.51) RNASEH1KMT2AMAPTMEN1MAPK1
SCHEMBL46037 0.75 MAPT (0.50) RNASEH1KMT2AMAPTMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 RNASEH1 813/4885KMT2A 2650/4885MAPT 1619/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 RNASEH1 813/4885KMT2A 2650/4885MAPT 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.